AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
Amgen (NASDAQ: AMGN) has announced its participation in the 35th Annual Oppenheimer Healthcare Life Sciences Conference scheduled for Wednesday, February 12, 2025, at 11:20 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amgen (NASDAQ: AMGN) has announced its participation in the 35th Annual Oppenheimer Healthcare Life Sciences Conference scheduled for Wednesday, February 12, 2025, at 11:20 a.m. ET. Narimon Honarpour, senior vice president of global development at Amgen, will represent the company at the conference.
The presentation will be accessible through a live webcast simultaneously available to investors, news media, and the general public. The webcast can be accessed through Amgen's website (www.amgen.com) under the Investors section, along with other management presentations from investor and medical conferences. The presentation will remain archived and available for replay on the website for a minimum of 90 days following the event.
Details
News Market Reaction – AMGN
The recorded move for AMGN in the trading session of this news was +0.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads.
CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-35th-annual-oppenheimer-healthcare-life-sciences-conference-302371476.html
SOURCE Amgen
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.